Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists

Brain Research

Volumn 1148, Issue 1, 2007, Pages 28-37

  Chen, Yi Ning ^a   Yamada, Hideyuki ^a   Mao, Wei ^a   Matsuyama, Shigemi ^b   Aihara, Makoto ^a   Araie, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bax inhibiting peptide; Beta adrenergic antagonist; Hypoxia; Retinal ganglion cell

Indexed keywords

6,7 DINITRO 2,3 QUINOXALINEDIONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM ION; CARTEOLOL; DIZOCILPINE; GLUTAMATE RECEPTOR; NIPRADILOL; PEPTIDE; PROTEIN BAX; TIMOLOL; UNCLASSIFIED DRUG; VALYLPROLYLTHREONYLLEUCYLLYSINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; HYPOXIA; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RETINA GANGLION CELL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CALCIUM; CALCIUM SIGNALING; CELL SURVIVAL; CELLS, CULTURED; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; GLAUCOMA; HYPOXIA-ISCHEMIA, BRAIN; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PEPTIDES; RATS; RECEPTORS, GLUTAMATE; RETINAL GANGLION CELLS;

RATTUS;

EID: 34247115175     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.02.027     Document Type: Article

References (63)

1. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., and Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30 (2002) 421-429
2. Carter-Dawson L., Crawford M.L., Harwerth R.S., Smith III E.L., Feldman R., Shen F.F., Mitchell C.K., and Whitetree A. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest. Ophthalmol. Visual Sci. 43 (2002) 2633-2637
3. Chidlow G., Melena J., and Osborne N.N. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br. J. Pharmacol. 130 (2000) 759-766
4. Chung H.S., Harris A., Evans D.W., Kagemann L., Garzozi H.J., and Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv. Ophthalmol. 43 (1999) S43-S50
5. Costa V.P., Harris A., Stefansson E., Flammer J., Krieglstein G.K., Orzalesi N., Heijl A., Renard J.P., and Serra L.M. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog. Retin. Eye Res. 22 (2003) 769-805
6. Drance S.M. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J. Glaucoma 7 (1998) 247-252
7. Drance S.M., Douglas G.R., Wijsman K., Schulzer M., and Britton R.J. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am. J. Ophthalmol. 15 (1988) 35-39
8. Flammer J. The vascular concept of glaucoma. Surv. Ophthalmol. 38 (1994) S3-S6
9. Goto W., Ota T., Morikawa N., Otori Y., Hara H., Kawazu K., Miyawaki N., and Tano Y. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 958 (2002) 10-19
10. Goto W., Ichikawa M., Tanaka E., Hara H., and Araie M. Bunazosin hydrochloride reduces glutamate-induced neurotoxicity in rat primary retinal cultures. Brain Res. 1003 (2004) 130-137
11. Gross R.L., Hensley S.H., Gao F., Yang X.L., Dai S.C., and Wu S.M. Effects of betaxolol on light responses and membrane conductance in retinal ganglion cells. Invest. Ophthalmol. Visual Sci. 41 (2000) 722-728
12. Hirooka K., Kelly M.E., Baldridge W.H., and Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. 70 (2000) 611-621
13. Honkanen R.A., Baruah S., Zimmerman M.B., Khanna C.L., Weaver Y.K., Narkiewicz J., Waziri R., Gehrs K.M., Weingeist T.A., Boldt H.C., Folk J.C., Russell S.R., and Kwon Y.H. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch. Ophthalmol. 121 (2003) 183-188
14. Ichikawa M., Okada Y., Asai Y., Hara H., Ishii K., and Araie M. Effects of topically instilled bunazosin, an alpha1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Invest. Ophthalmol. Visual Sci. 45 (2004) 4041-4048
15. Ishii K., Matsuo H., Fukaya Y., Tanaka S., Sakaki H., Waki M., and Araie M. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation. Invest. Ophthalmol. Visual Sci. 44 (2003) 1169-1177
16. Kageyama T., Ishikawa A., and Tamai M. Glutamate elevation in rabbit vitreous during transient ischemia-reperfusion. Jpn. J. Ophthalmol. 44 (2000) 110-114
17. Kaiser H.J., Flammer J., Stumpfig D., and Hendrickson P. Long term visual field follow-up of glaucoma patients treated with beta-blockers. Surv. Ophthalmol. 38 (1994) S156-S159 (discussion S160)
18. Kashiwagi K., Iizuka Y., and Tsukahara S. Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. J. Glaucoma 11 (2002) 231-238
19. Kashiwakura I., Kuwabara M., Murakami M., Hayase Y., and Takagi Y. Effect of carboxy-PTIO, a nitric oxide scavenger, on the proliferation of murine hematopoietic progenitor cells in vitro. Res. Commun. Mol. Pathol. Pharmacol. 99 (1998) 329-337
20. Kawasaki Y., Fujikado T., Hosohata J., Tano Y., and Tanaka Y. The effect of nitric oxide on the contractile tone of Muller cells. Ophthalmic Res. 31 (1999) 387-391
21. Kroemer G., and Martin S.J. Caspase-independent cell death. Nat. Med. 11 (2005) 725-730
22. Kubrusly R.C., de Mello M.C., and de Mello F.G. Aspartate as a selective NMDA receptor agonist in cultured cells from the avian retina. Neurochem. Int. 32 (1998) 47-52
23. Lagreze W.A., Knorle R., Bach M., and Feuerstein T.J. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Visual Sci. 39 (1998) 1063-1066
24. Levkovitch-Verbin H., Martin K.R., Quigley H.A., Baumrind L.A., Pease M.E., and Valenta D. Measurement of amino acid levels in the vitreous humor of rats after chronic intraocular pressure elevation or optic nerve transection. J. Glaucoma 11 (2002) 396-405
25. Li Y., Schlamp C.L., Poulsen K.P., and Nickells R.W. Bax-dependent and independent pathways of retinal ganglion cell death induced by different damaging stimuli. Exp. Eye Res. 71 (2000) 209-213
26. Messmer C., Flammer J., and Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am. J. Ophthalmol. 112 (1991) 678-681
27. Mizuno K., Koide T., Yoshimura M., and Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest. Ophthalmol. Visual Sci. 42 (2001) 688-694
28. Munsch T., and Deitmer J.W. Intracellular Ca2+, Na+ and H+ transients evoked by kainate in the leech giant glial cells in situ. Neurosci. Res. 27 (1997) 45-56
29. Neal M.J., Cunningham J.R., Hutson P.H., and Hogg J. Effects of ischaemia on neurotransmitter release from the isolated retina. J. Neurochem. 62 (1994) 1025-1033
30. Ohia S.E., Awe O.S., Opere C.A., LeDay A.M., Harris L.C., and Sharif N.A. Hypoxia-induced [(3)H]d-aspartate release from isolated bovine retina: modulation by calcium-channel blockers and glutamatergic agonists and antagonists. Curr. Eye Res. 23 (2001) 386-392
31. Ohira A., Wada Y., Fujii M., Nakamura M., Kasuya Y., Hamada Y., and Shigenobu K. Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch. Int. Pharmacodyn. Ther. 278 (1985) 61-71
32. Okamura T., Kitamura Y., Uchiyama M., Toda M., Ayajiki K., and Toda N. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic. Pharmacology 53 (1996) 302-310
33. Okamura T., Fujioka H., and Ayajiki K. Effects of nipradilol on alpha-adrenoceptor function in ocular arteries. Pharmacology 65 (2002) 110-118
34. Osborne N.N., Cazevieille C., Carvalho A.L., Larsen A.K., and DeSantis L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751 (1997) 113-123
35. Osborne N.N., DeSantis L., Bae J.H., Ugarte M., Wood J.P., Nash M.S., and Chidlow G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 69 (1999) 331-342
36. Osborne N.N., Ugarte M., Chao M., Chidlow G., Bae J.H., Wood J.P., and Nash M.S. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. 43 (1999) S102-S128
37. Osborne N.N., Wood J.P., Chidlow G., Casson R., DeSantis L., and Schmidt K.G. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res. Bull. 62 (2004) 525-528
38. Otori Y., Wei J.Y., and Barnstable C.J. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest. Ophthalmol. Visual Sci. 39 (1998) 972-981
39. Parsons A.M., Sorman J.L., and El-Fakahany E.E. Regulation of M1 muscarinic receptor-mediated signaling in intact cells by exogenous, but not endogenously produced, nitric oxide. Neurochem. Res. 24 (1999) 85-94
40. Qin Q., Patil K., and Sharma S.C. The role of Bax-inhibiting peptide in retinal ganglion cell apoptosis after optic nerve transection. Neurosci. Lett. 372 (2004) 17-21
41. Quigley H.A. Neuronal death in glaucoma. Prog. Retin. Eye Res. 18 (1999) 39-57
42. Rego A.C., Santos M.S., and Oliveira C.R. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J. Neurochem. 66 (1996) 2506-2516
43. Sawada M., Sun W., Hayes P., Leskov K., Boothman D.A., and Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol. 5 (2003) 320-329
44. Sawada M., Hayes P., and Matsuyama S. Inhibition of Bax-mediated apoptosis by the peptide designed from Bax-biding domain in Ku70. Nat. Cell Biol. 5 (2003) 352-357
45. Schutte B., Nuydens R., Geerts H., and Ramaekers F. Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J. Neurosci. Methods 86 (1998) 63-69
46. Shirasawa Y., Fujii M., and Nakamura M. Venodilating action of nipradilol (K-351) in the pithed rat pretreated with dihydroergotamine. Jpn. J. Pharmacol. 39 (1985) 77-82
47. Tezel G., and Wax M.B. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest. Ophthalmol. Visual Sci. 40 (1999) 2660-2667
48. Tezel G., and Wax M.B. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J. Neurosci. 20 (2000) 8693-8700
49. Tezel G., and Wax M.B. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch. Ophthalmol. 122 (2004) 1348-1356
50. Tezel G., and Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest. Ophthalmol. Visual Sci. 45 (2004) 4049-4059
51. Tielsch J.M., Katz J., Sommer A., Quigley H.A., and Javitt J.C. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch. Ophthalmol. 113 (1995) 216-221
52. Uchida Y., Nakamura M., Shimizu S., Shirasawa Y., and Fujii M. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch. Int. Pharmacodyn. Ther. 262 (1983) 132-149
53. Uchida S., Suzuki Y., Araie M., Kashiwagi K., Otori Y., and Sakuragawa N. Factors secreted by human amniotic epithelial cells promote the survival of rat retinal ganglion cells. Neurosci. Lett. 341 (2003) 1-4
54. Vorwerk CK., Naskar R., Schuettauf F., Quinto K., Zurakowski D., Gochenauer G., Robinson M.B., Mackler S.A., and Dreyer E.B. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest. Ophthalmol. Visual Sci. 41 (2000) 3615-3621
55. Wax M.B., and Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol. Neurobiol. 26 (2002) 45-55
56. Won S.J., Kim D.Y., and Gwag B.J. Cellular and molecular pathways of ischemic neuronal death. J. Biochem. Mol. Biol. 35 (2002) 67-86
57. Wood J.P., DeSantis L., Chao H.M., and Osborne N.N. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72 (2001) 79-86
58. Wood J.P., Schmidt K.G., Melena J., Chidlow G., Allmeier H., and Osborne N.N. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 76 (2003) 505-516
59. Yamada H., Chen Y.N., Aihara M., and Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res. 1071 (2006) 75-80
60. Yoles E., and Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 116 (1998) 906-910
61. Yoshida T., Tomioka I., and Nagahara T. New Bax-inhibiting peptides (BIPs) derived from mouse and rat Ku70. Biochem. Biophys. Res. Commun. 321 (2004) 961-966
62. Zeevalk G.D., and Nicklas W.J. Action of the anti-ischemic agent ifenprodil on N-methyl-d-aspartate and kainate-mediated excitotoxicity. Brain Res. 522 (1990) 135-139
63. Zhang J., Wu S.M., and Gross R.L. Effects of beta-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res. 959 (2003) 111-119